Tobacco Assessment in Actively Accruing National Cancer Institute Clinical Trials Network Trials

In 2012, few (< 30%) cancer clinical trials evaluated tobacco use at enrollment and < 5% did so during follow-up, prompting efforts to promote and standardize tobacco assessment in oncology research and practice (including the development of the Cancer Patient Tobacco Use Questionnaire [C-TUQ]). The present study builds on this foundational paper and finds an overall increase in tobacco use assessment with room for improvement: 49.3% of trials in 2022 assessed tobacco use at enrollment and 8.3% did so during follow-up. About 20.8% used at least one C-TUQ question, highlighting that tobacco use assessment is not yet fully incorporated into oncology clinical trials.

Authors

Institutions

Publication Details

Journal
Nicotine & Tobacco Research
Published
2025-03-22
DOI
https://doi.org/10.1093/ntr/ntaf071
Citations
1
Primary Topic
Global Cancer Incidence and Screening
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Tobacco Assessment in Actively Accruing National Cancer Institute Clinical Trials Network Trials

Marcia H. McCall, Amanda M. Palmer, Benjamin A. Toll, Margaret C. Fahey et al.
1 citations
Nicotine & Tobacco Research
Global Cancer Incidence and Screening
article

Tobacco Assessment in Actively Accruing National Cancer Institute Clinical Trials Network Trials

Marcia H. McCall, Amanda M. Palmer, Benjamin A. Toll, Margaret C. Fahey, Ivana T. Croghan, Kinsey Pebley, Stephanie R. Land, Lynne I. Wagner, Sarah N. Price, Alana M. Rojewski, Pamela J. Raper
article en
1 citations

Abstract

In 2012, few (< 30%) cancer clinical trials evaluated tobacco use at enrollment and < 5% did so during follow-up, prompting efforts to promote and standardize tobacco assessment in oncology research and practice (including the development of the Cancer Patient Tobacco Use Questionnaire [C-TUQ]). The present study builds on this foundational paper and finds an overall increase in tobacco use assessment with room for improvement: 49.3% of trials in 2022 assessed tobacco use at enrollment and 8.3% did so during follow-up. About 20.8% used at least one C-TUQ question, highlighting that tobacco use assessment is not yet fully incorporated into oncology clinical trials.

Nicotine & Tobacco ResearchVol. 27(10)
University of North Carolina at Chapel Hill (US), Medical University of South Carolina (US), Middle Tennessee State University (US), MUSC Hollings Cancer Center (US), National Cancer Institute (UA), Mayo Clinic in Arizona (US), National Cancer Institute (US), Mayo Clinic in Florida (US), Department of Health (ZA), Wake Forest University (US)
Good health and well-being
Openalex Percentile: Top 92%
Global Cancer Incidence and Screening
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.